Location · Sandy Springs, GA
Clinical trials in Sandy Springs, GA
10 recruiting studies have a site in Sandy Springs, and 0 of them accept healthy volunteers.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Sanofi
- Location
- Sandy Springs, GA + 118 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 2/Phase 3
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Priovant Therapeutics, Inc.
- Location
- Sandy Springs, GA + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Sanofi
- Location
- Sandy Springs, GA + 126 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Sandy Springs, GA + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Sandy Springs, GA + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Sandy Springs, GA + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Sandy Springs, GA + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Sandy Springs, GA + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Sandy Springs, GA + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLC
- Location
- Sandy Springs, GA + 23 other US sites
- Eligibility basics
- Ages 18+